A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries

Globalization and Health

Volumn 7, Issue , 2011, Pages

  Moon, Suerie ^a   Jambert, Elodie ^b   Childs, Michelle ^b   von Schoen Angerer, Tido ^b  

^a HARVARD UNIVERSITY   (United States)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

Access to medicines; Developing countries; Differential pricing; Drugs; Essential medicines; Low and middle income countries (lmic); Market segmentation; Pharmaceuticals; Tiered pricing

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ARTEMETHER PLUS BENFLUMETOL; ARTEMISIN DERIVATIVE; ATAZANAVIR; CAPREOMYCIN; CYCLOSERINE; LOPINAVIR PLUS RITONAVIR; PNEUMOCOCCUS VACCINE; PROTEINASE INHIBITOR; TUBERCULOSTATIC AGENT;

CRITICAL ANALYSIS; DECISION MAKING; DEVELOPING WORLD; DRUG; GLOBALIZATION; HEALTH EXPENDITURE; MARKET TRANSITION; MEDICINE; PUBLIC ACCESS; SUSTAINABILITY; VACCINE;

ARTICLE; DEVELOPING COUNTRY; DRUG COST; DRUG INDUSTRY; HEALTH CARE ACCESS; INDUSTRIALIZATION; PRIORITY JOURNAL;

HARNESS;

EID: 80053916778     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-7-39     Document Type: Article

References (56)

1. World Bank How we classify countries. 2009, World Bank., http://data.worldbank.org/about/country-classifications
2. Danzon PM, Towse A. Differential pricing for pharmaceuticals: Reconciling access, R&D and patents. AEI-Brookings Joint Center Working Paper No. 03-7 2003, , http://ssrn.com/abstract=422821
3. Moon S. Medicines as global public goods: The governance of technological innovation in the new era of global health. Glob Health Gov 2009, 2:1-23., http://www.ghgj.org/moon2.2medecinespublicgood.htm
4. Sukkar E. UK kick-starts differential pricing debate for developing world. Scrip World News 2009, 28-29.
5. European Union Essential Medicines for Developing Countries (HIV/AIDS, Tuberculosis and Malaria). 2006, European Union., http://europa.eu/legislation_summaries/development/sectoral_development_policies/l21166_en.htm
6. Mackay B. Summary report of Industry Government Forum on Access to Medicines (IGFAM). 2009, London: DFID Health Resources Center. Meeting report.
7. Witty A. Big pharma as a catalyst for change. February 13, 2009 Speech to Harvard Medical School. 2009, , http://www.gsk.com/media/downloads/Witty-Harvard-Speech-Summary.pdf
8. Yadav P. Differential pricing of pharmaceuticals: Review of current knowledge, new findings and ideas for action. A study conducted for the UK Department for International Development (DFID). Zaragoza, Spain: MIT-Zaragoza International Logistics Program 2010, , http://www.dfid.gov.uk/Documents/publications1/prd/diff-pcing-pharma.pdf
9. Plahte J. Tiered pricing of vaccines: A win-win-win situation, not a subsidy. Lancet Infect Dis 2005, 5:58-63. 10.1016/S1473-3099(04)01255-1, 15620562.
10. Ramsey FP. A contribution to the theory of taxation. Econ J 1927, 37:47-61.
11. WHO The world drug situation. 1988, Geneva, WHO.
12. Xu K, Evans D, Kawabata K, Zeramdini R, Klavus J, Murray CJ. Household catastrophic health expenditure: a multicountry analysis. Lancet 2003, 362:111-117. 10.1016/S0140-6736(03)13861-5, 12867110.
13. WHO Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). Public Health, Innovation and Intellectual Property Rights 2006, Geneva, WHO.
14. Niëns L, Brouwer W. Better measures of affordability required. Lancet 2009, 373:1081.
15. Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF, Laing R. Quantifying the impoverishing effects of purchasing medicines: A cross-country comparison of the affordability of medicines in the developing world. PLoS Med 2010, 7:e1000333. 10.1371/journal.pmed.1000333, 2930876, 20824175.
16. Waning B, Kaplan W, King AC, Lawrence DA, Leufkens HG, Fox MP. Global strategies to reduce the price of antiretroviral medicines. Evidence from transactional databases. Bull World Health Organ 2009, 87:520-528. 10.2471/BLT.08.058925, 2704041, 19649366.
17. Médecins Sans Frontières (MSF), Campaign for Access to Essential Medicines Untangling the web of antiretroviral price reductions (online edition). 2011, 14, Médecins Sans Frontières (MSF), Campaign for Access to Essential Medicines., http://utw.msfaccess.org/
18. Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. J Econ Manag Strategy 1997, 6:75-90.
19. Baker BK, Ombaka E. The danger of in-kind drug donations to the Global Fund. Lancet 2009, 373:1218-1221. 10.1016/S0140-6736(08)61487-7, 18848353.
20. Waning B, Kyle M, Diedrichsen E, Soucy L, Hochstadt J, Bärnighausen T, Moon S. Intervening in global markets to improve access to HIV/AIDS treatment: An analysis of international policies and the dynamics of global antiretroviral medicines markets. Global Health 2010, 6:9. 10.1186/1744-8603-6-9, 2883977, 20500827.
21. WHO Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents. 2009, Geneva, WHO.
22. WHO Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. 2009, Geneva, WHO.
23. Perez-Casas C, Mace C, Berman D, Double J. Untangling the web of antiretroviral price reductions. 1st ed. Médecins Sans Frontières, Campaign for Access to Essential Medicines 2001, 3191741, 22007351., http://utw.msfaccess.org/downloads/311
24. Médecins Sans Frontières (MSF), Campaign for Access to Essential Medicines Untangling the web of antiretroviral price reductions. 2005, 8, Médecins Sans Frontières (MSF), Campaign for Access to Essential Medicines., http://utw.msfaccess.org/downloads/161
25. Waning B, Diedrichsen E, Moon S. Market shift towards heat-stable lopinavir/ritonavir demonstrates the need for improved formulations for second-line treatment of HIV/AIDS in low- and middle-income countries. Poster Presentation, XVIII International AIDS Conference 2010, Vienna.
26. Carreyrou J. New regimen: Inside Abbott's tactics to protect AIDS drug. Wall St J 2007,
27. Safeway Inc., et al. v. Abbott Laboratories: Hon. C. Wilken, California Northern District Court, case number 4:2007cv05470. 2007, , http://dockets.justia.com/docket/california/candce/4:2007cv05470/197311/
28. Law360 9th Circ. rejects rehearing on Norvir antitrust deal. 2009, New York, Law360., http://www.law360.com/articles/117786
29. WHO WHO and Novartis join forces to combat drug resistant malaria. 2001, WHO.
30. Moon S, Pérez Casas C, Kindermans J, de Smet M, von Schoen-Angerer T. Focusing on quality patient care in the new global subsidy for malaria medicines. PLoS Med 2009, 6:e1000106. 10.1371/journal.pmed.1000106, 2706998, 19621068.
31. Médecins Sans Frontières (MSF) and International Union Against Tuberculosis and Lung Disease (IUATLD) DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines. 2011, Médecins Sans Frontières (MSF) and International Union Against Tuberculosis and Lung Disease (IUATLD)., http://www.msfaccess.org/sites/default/files/MSF_assets/TB/Docs/TB_report_UndertheMicro_ENG_2011.pdf
32. British National Formulary. 2010, 60.
33. WHO Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update. 2008, Geneva, WHO.
34. WHO Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. 2011, Geneva, WHO.
35. Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006, 43:917-924. 10.1086/507530, 16941377.
36. GAVI Alliance Advance Market Commitment for Pneumococcal Vaccines: Annual Report 12 June 2009-31 March 2010. 2010, Geneva, GAVI Alliance.
37. GAVI Alliance Who can apply. 2011, GAVI Alliance., http://www.gavialliance.org/support/who/index.php
38. Jack A. GSK signs lifetime deal with Brazil for pneumococcal vaccine. Financ Times 2009,
39. Wilson P. Giving developing countries the best shot: An overview of vaccine access and R&D. Oxfam International and MSF Campaign for Access to Essential Medicines. Geneva: 2010,
40. Yadav P. Differential pricing: The interface of economics and supply chains. 2009, London, Presented at DFID Industry-Government Forum on Access to Medicines..
41. TB Alliance Pathway to Patients: Charting the Dynamics of the Global TB Drug Market. Global Alliance for TB Drug Development, New York 2007, TB Alliance., http://www.tballiance.org/aaa/groundwork.php
42. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. Lancet 2009, 373:240-249. 10.1016/S0140-6736(08)61762-6, 19042012.
43. United Nations Development Programme (UNDP) Human Development Report 2009: Overcoming Barriers: Human Mobility and Development. 2009, New York, United Nations Development Programme (UNDP)., http://hdrstats.undp.org/en/indicators/161.html
44. Wong EV. Inequality and pharmaceutical drug prices: An empirical exercise. Discussion Papers in Economics. Center for Economic Analysis, Department of Economics, University of Colorado, Boulder, CO. Working Paper 02-19
45. Ford N, Wilson D, Chaves GC, Lotrowska M, Kijtiwatchakul K. Sustaining access to antiretroviral therapy in the less-developed world: Lessons from Brazil and Thailand. AIDS 2007, 21(Suppl 4):S21-S29. 10.1097/01.aids.0000279703.78685.a6, 18090264.
46. Lopert R, Lang DL, Hill SR, Henry DA. Differential pricing of drugs: A role for cost-effectiveness analysis?. Lancet 2002, 359:2105-2107. 10.1016/S0140-6736(02)08911-0, 12086780.
47. Organisation for Economic Cooperation and Development (OECD) Pharmaceutical Pricing Policies in a Global Market. OECD Health Policy Studies 2008, Organisation for Economic Cooperation and Development (OECD).
48. 't Hoen E. The global politics of pharmaceutical monopoly power: Drug patents, access, innovation, and the application of the WTO Doha Declaration on TRIPS and public health. 2009, Diemen, the Netherlands: AMB Press.
49. Medicines Patent Pool. 2010, Geneva., http://www.medicinespatentpool.org
50. Hubbard T, Love J. A new trade framework for global healthcare R&D. PLoS Biol 2004, 2:e52. 10.1371/journal.pbio.0020052, 340954, 14966544.
51. Finkelstein SN, Temin P. Reasonable Rx: Solving the Drug Price Crisis. Upper Saddle River, NJ: FT Press/Pearson Education 2008,
52. Bermudez J, 't Hoen E. The UNITAID Patent Pool Initiative: Bringing patents together for the common good. Open AIDS J 2010, 4:37-40. 10.2174/1874613601004020037, 2842943, 20309404.
53. Outterson K. Patent buy-outs for global disease innovations for low- and middle-income countries. Am J Law Med 2006, 32:159-173.
54. Global Fund to Fight AIDS, Tuberculosis and Malaria Global Fund Price and Quality Reporting. 2010, Global Fund to Fight AIDS, Tuberculosis and Malaria., http://pqr.theglobalfund.org
55. Management Sciences for Health International Drug Price Indicator Guide. Capreomycin. 2009, Management Sciences for Health., http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=CAPR1I&s_year=2009&year=2009&str=1%20g&desc=Capreomycin&pack=new&frm=VIAL&rte=INJ&class_code2=06.2.4.&supplement=&class_name=(06.2.4.)Antituberculosis%20medicines%3Cbr%3E
56. Management Sciences for Health International Drug Price Indicator Guide. Cycloserine. 2009, Management Sciences for Health., http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=CYCS250T&s_year=2009&year=2009&str=250%20mg&desc=Cycloserine&pack=new&frm=TAB-CAP&rte=PO&class_code2=06.2.4.&supplement=&class_name=(06.2.4.)Antituberculosis%20medicines%3Cbr%3E